MARKET

RVNC

RVNC

Revance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.15
+0.09
+0.31%
After Hours: 29.98 +0.83 +2.85% 17:13 05/17 EDT
OPEN
28.44
PREV CLOSE
29.06
HIGH
29.29
LOW
28.34
VOLUME
279.18K
TURNOVER
--
52 WEEK HIGH
34.62
52 WEEK LOW
19.37
MARKET CAP
2.09B
P/E (TTM)
-6.1102
1D
5D
1M
3M
1Y
5Y
Is Revance Therapeutics (NASDAQ:RVNC) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St. · 6d ago
Dermal Fillers Market Size 2021 | Is Likely to Reach USD 6.64 Billion by 2027, Registering a CAGR of 9.3%
Dermal Fillers Market Size| 2021 Covid-19 Impact On Automotive Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2027 is latest study published by Fortune Bus...
GlobeNewswire · 6d ago
--Mizuho Securities Adjusts Price Target on Revance Therapeutics to $36 From $37, Maintains Buy Rating
MT Newswires · 6d ago
8-K: Revance Therapeutics, Inc.
(EDGAR Online via COMTEX) -- 00014792905/10/2021FALSE00014792902021-05-102021-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 05/10 23:05
BRIEF-Revance Posts Quarterly Loss Per Share Of $1.08
reuters.com · 05/10 22:18
Recap: Revance Therapeutics Q1 Earnings
Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the past year to ($1.08), which beat the estimate of ($1.09).
Benzinga · 05/10 21:00
Revance Therapeutics Q1 EPS $(1.08) Beats $(1.09) Estimate, Sales $13.30M Beat $10.98M Estimate
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.09) by 0.92 percent. This is a 6.09 percent increase over losses of $(1.15) per share
Benzinga · 05/10 20:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RVNC. Analyze the recent business situations of Revance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RVNC stock price target is 38.50 with a high estimate of 55.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 61.63M
% Owned: 86.16%
Shares Outstanding: 71.53M
TypeInstitutionsShares
Increased
44
3.29M
New
8
60.66K
Decreased
33
1.00M
Sold Out
11
938.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Angus Russell
President/Chief Executive Officer/Director
Mark Foley
Chief Financial Officer
Tobin Schilke
Corporate Executive/Director
Aubrey Rankin
Chief Operating Officer
Abhay Joshi
Senior Vice President/General Counsel/Secretary
Dwight Moxie
Other
Dustin Sjuts
Independent Director
Jill Beraud
Independent Director
Julian Gangolli
Independent Director
Carey Kolaja
Independent Director
Chris Nolet
Independent Director
Philip Vickers
Independent Director
Olivia Ware
No Data
About RVNC
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.